MR-Guided Radiotherapy for Rectal Cancer: Current Perspective on Organ Preservation

Luca Boldrini, Martijn Intven, Michael Bassetti, Vincenzo Valentini, Cihan Gani, Luca Boldrini, Martijn Intven, Michael Bassetti, Vincenzo Valentini, Cihan Gani

Abstract

Online MRI-guided radiotherapy (MRgRT) is one of the most recent technological advances in radiotherapy. MRgRT permits the visualization of tumorous and healthy tissue while the patient is on the treatment table and online daily plan adaptations following the observed anatomical changes. In the context of rectal cancer, online MRgRT is a very promising modality due to the pronounced geographical variability of tumor tissues and the surrounding healthy tissues. This current paper will discuss the possible applications of online MRgRT, in particular, in terms of radiotherapy dose escalation and response prediction in organ preservation approaches for rectal cancer.

Keywords: MR-linac; MRI; dose escalation; radiotherapy; rectal cancer.

Conflict of interest statement

LB has active research agreements with ViewRay Inc and has received speaker honoraria for scientific presentations. CG: University Hospital Tübingen receives financial and technical support, including costs for travels (CG) and symposia from Elekta AB (Stockholm, Sweden), under a research agreement. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Boldrini, Intven, Bassetti, Valentini and Gani.

Figures

Figure 1
Figure 1
Representative scans from the 0.35 T MR LINAC (A–C) in the coronal, sagittal, and transverse planes and the 1.5 T MR LINAC (D–F) in the coronal, sagittal, and transverse planes. In both cases, a patient with a distally located rectal tumur was scanned. Arrows indicate the tumur.

References

    1. Sauer R, Liersch T, Merkel S, Fietkau R, Hohenberger W, Hess C, et al. . Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. (2012) 30:1926–33. 10.1200/JCO.2011.40.1836
    1. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, et al. . Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (2017) 28:iv22–40. 10.1093/annonc/mdx224
    1. Curvo-Semedo L. Rectal cancer: staging. Magn Reson Imaging Clin N Am. (2020) 28:105–15. 10.1016/j.mric.2019.09.003
    1. Chiloiro G, Boldrini L, Meldolesi E, Re A, Cellini F, Davide C, et al. . MR-guided radiotherapy in rectal cancer: first clinical experience of an innovative technology. Clin Transl Radiat Oncol. (2019) 18:80–6. 10.1016/j.ctro.2019.04.006
    1. Klüter S. Technical design and concept of a 0.35 T MR-Linac. Clin Transl Radiat Oncol. (2019) 18:98–101. 10.1016/j.ctro.2019.04.007
    1. Slotman B, Gani C. Online MR-guided radiotherapy – a new era in radiotherapy. Clin Transl Radiat Oncol. (2019) 18:102–3. 10.1016/j.ctro.2019.04.011
    1. Winkel D, Bol GH, Kroon PS, van Asselen B, Hackett SS, Werensteijn-Honingh AM, et al. . Adaptive radiotherapy: the Elekta Unity MR-linac concept. Clin Transl Radiat Oncol.. (2019) 18:102–3.
    1. Gani C, Boldrini L, Valentini V. Online MR guided radiotherapy for rectal cancer. New opportunities. Clin Transl Radiat Oncol. (2019) 18:66–7. 10.1016/j.ctro.2019.04.005
    1. Gani C, Bonomo P, Zwirner K, Schroeder C, Menegakis A, Rodel C, et al. . Organ preservation in rectal cancer - challenges and future strategies. Clin Transl Radiat Oncol. (2017) 3:9–15. 10.1016/j.ctro.2017.02.002
    1. Maas M, Beets-Tan RG, Lambregts DM, Lammering G, Nelemans PJ, Engelen SM, et al. . Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. (2011) 29:4633–40. 10.1200/JCO.2011.37.7176
    1. Gani C, Kirschniak A, Zips D. Watchful Waiting after Radiochemotherapy in Rectal Cancer: When Is It Feasible? Visc Med. (2019) 35:119–23. 10.1159/000499167
    1. Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, et al. . Effect of interval (7 or 11 weeks) between neoadjuvant radiochemotherapy and surgery on complete pathologic response in rectal cancer: a multicenter, randomized, controlled trial (GRECCAR-6). J Clin Oncol. (2016) 34:3773–80. 10.1200/JCO.2016.67.6049
    1. Gani C, Schroeder C, Lamprecht U, Bamberg M, Berger B. Rates of pathologic complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with or without regional pelvic hyperthermia for locally advanced rectal cancer. J Clin Oncol. (2012) 30:622. 10.1200/jco.2012.30.4_suppl.622
    1. Burbach JP, den Harder AM, Intven M, van Vulpen M, Verkooijen HM, Reerink O. Impact of radiotherapy boost on pathological complete response in patients with locally advanced rectal cancer: a systematic review and meta-analysis. Radiother Oncol. (2014) 113:1–9. 10.1016/j.radonc.2014.08.035
    1. Rödel C, Liersch T, Becker H, Fietkau R, Hohenberger W, Hothorn T, et al. . Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol. (2012) 13:679–87. 10.1016/S1470-2045(12)70187-0
    1. Garcia-Aguilar J, Chow OS, Smith DD, Marcet JE, Cataldo Pa, Varma MG, et al. . Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol. (2015) 2045:1–10. 10.1016/S1470-2045(15)00004-2
    1. Ippolito E, Mertens I, Haustermans K, Gambacorta MA, Pasini D, Valentini V. IGRT in rectal cancer. Acta Oncol. (2008) 47:1317–24. 10.1080/02841860802256459
    1. Nijkamp J, de Jong R, Sonke JJ, Remeijer P, van Vliet C, Marijnen C. Target volume shape variation during hypo-fractionated preoperative irradiation of rectal cancer patients. Radiother Oncol. (2009) 92:202–9. 10.1016/j.radonc.2009.04.022
    1. Brierley JD, Dawson LA, Sampson E, Bayley A, Scott S, Moseley JL, et al. . Rectal motion in patients receiving preoperative radiotherapy for carcinoma of the rectum. Int J Radiat Oncol Biol Phys. (2011) 80:97–102. 10.1016/j.ijrobp.2010.01.042
    1. Roels S, Slagmolen P, Nuyts J, Lee JA, Loeckx D, Maes F, et al. . Biological image-guided radiotherapy in rectal cancer: challenges and pitfalls. Int J Radiat Oncol Biol Phys. (2009) 75:782–90. 10.1016/j.ijrobp.2008.11.031
    1. Van den Begin R, Kleijnen JP, Engels B, Philippens M, van Asselen B, Raaymakers B, et al. . Tumor volume regression during preoperative chemoradiotherapy for rectal cancer: a prospective observational study with weekly MRI. Acta Oncol. (2018) 57:723–7. 10.1080/0284186X.2017.1400689
    1. Chris B, Baukelien vT, Suzanne vB, Jan-Jakob S, Peter R. Margin and PTV volume reduction using a population based library of plans strategy for rectal cancer radiotherapy. Medical Physics. (2018)
    1. Intven MPW, de Mol van Otterloo SR, Mook S, Doornaert PAH, de Groot-van Breugel EN, Sikkes GG, et al. . Online adaptive MR-guided radiotherapy for rectal cancer; feasibility of the workflow on a 1.5T MR-linac; clinical implementation and initial experience. Radiother Oncol. (2020) 154:172–8. 10.1016/j.radonc.2020.09.024
    1. Gani C, Gani N, Zschaeck S, Eberle F, Schaeffeler N, Hehr T, et al. . Organ preservation in rectal cancer: the patients' perspective. Front Oncol. (2019) 9:318. 10.3389/fonc.2019.00318
    1. Appelt AL, Ploen J, Vogelius IR, Bentzen SM, Jakobsen A. Radiation dose-response model for locally advanced rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys. (2013) 85:74–80. 10.1016/j.ijrobp.2012.05.017
    1. Couwenberg AM, Burbach JPM, Berbee M, Lacle MM, Arensman R, Raicu MG, et al. . Efficacy of dose-escalated chemoradiation on complete tumor response in patients with locally advanced rectal cancer (RECTAL-BOOST): a phase 2 randomized controlled trial. Int J Radiat Oncol Biol Phys. (2020) 108:1008–18. 10.1016/j.ijrobp.2020.06.013
    1. Valentini V, Gambacorta MA, Cellini F, Aristei C, Coco C, Barbaro B, et al. . The INTERACT Trial: Long-term results of a randomised trial on preoperative capecitabine-based radiochemotherapy intensified by concomitant boost or oxaliplatin, for cT2 (distal)-cT3 rectal cancer. Radiother Oncol. (2019) 134:110–8. 10.1016/j.radonc.2018.11.023
    1. Burbach JP, Verkooijen HM, Intven M, Kleijnen JP, Bosman ME, Raaymakers BW, et al. . RandomizEd controlled trial for pre-operAtive dose-escaLation BOOST in locally advanced rectal cancer (RECTAL BOOST study): study protocol for a randomized controlled trial. Trials. (2015) 16:58. 10.1186/s13063-015-0586-4
    1. Passoni P, Fiorino C, Slim N, Ronzoni M, Ricci V, Di Palo S, et al. . Feasibility of an adaptive strategy in preoperative radiochemotherapy for rectal cancer with image-guided tomotherapy: boosting the dose to the shrinking tumor. Int J Radiat Oncol Biol Phys. (2013) 87:67–72. 10.1016/j.ijrobp.2013.05.004
    1. Bonomo P, Lo Russo M, Nachbar M, Boeke S, Gatidis S, Zips D, et al. . 1.5 T MR-linac planning study to compare two different strategies of rectal boost irradiation. Clin Transl Radiat Oncol. (2020) 26:86–91. 10.1016/j.ctro.2020.11.016
    1. Olsson CE, Jackson A, Deasy JO, Thor M. A systematic post-QUANTEC review of tolerance doses for late toxicity after prostate cancer radiation therapy. Int J Radiat Oncol Biol Phys. (2018) 102:1514–32. 10.1016/j.ijrobp.2018.08.015
    1. Joye I, Deroose CM, Vandecaveye V, Haustermans K. The role of diffusion-weighted MRI and 18 F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiotherapy Oncol. (2014) 113:158–65. 10.1016/j.radonc.2014.11.026
    1. Thorwarth D, Ege M, Nachbar M, Mönnich D, Gani C, Zips D, et al. . Quantitative magnetic resonance imaging on hybrid magnetic resonance linear accelerators: Perspective on technical and clinical validation. Phys Imaging Radiation Oncol. (2020) 16:69–73. 10.1016/j.phro.2020.09.007
    1. Lambrecht M, Vandecaveye V, De Keyzer F, Roels S, Penninckx F, Van Cutsem E, et al. . Value of diffusion-weighted magnetic resonance imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: preliminary results. Int J Radiat Oncol Biol Phys. (2012) 82:863–70. 10.1016/j.ijrobp.2010.12.063
    1. Shaverdian N, Yang Y, Hu P, Hart S, Sheng K, Lamb J, et al. . Feasibility evaluation of diffusion-weighted imaging using an integrated MRI-radiotherapy system for response assessment to neoadjuvant therapy in rectal cancer. Br J Radiol. (2017) 90:20160739. 10.1259/bjr.20160739
    1. Boldrini L, Cusumano D, Chiloiro G, Casa C, Masciocchi C, Lenkowicz J, et al. . Delta radiomics for rectal cancer response prediction with hybrid 0.35 T magnetic resonance-guided radiotherapy (MRgRT): a hypothesis-generating study for an innovative personalized medicine approach. Radiol Med. (2019) 124:145–53. 10.1007/s11547-018-0951-y
    1. Cusumano D, Boldrini L, Yadav P, Yu G, Musurunu B, Chiloiro G, et al. . External validation of early regression index (ERITCP) as predictor of pathologic complete response in rectal cancer using magnetic resonance-guided radiation therapy. Int J Radiat Oncol Biol Phys. (2020) 10.1016/j.ijrobp.2020.07.2323

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren